1. Home
  2. NODK vs ALXO Comparison

NODK vs ALXO Comparison

Compare NODK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NODK

NI Holdings Inc.

HOLD

Current Price

$13.93

Market Cap

265.8M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.05

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NODK
ALXO
Founded
1946
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.8M
240.8M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
NODK
ALXO
Price
$13.93
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
11.6K
906.5K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
0.60
N/A
Revenue
$285,050,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.11
$0.41
52 Week High
$14.70
$2.66

Technical Indicators

Market Signals
Indicator
NODK
ALXO
Relative Strength Index (RSI) 68.61 58.24
Support Level $13.03 $1.99
Resistance Level $14.34 $2.30
Average True Range (ATR) 0.27 0.17
MACD 0.11 0.04
Stochastic Oscillator 90.24 77.95

Price Performance

Historical Comparison
NODK
ALXO

About NODK NI Holdings Inc.

NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: